Liquidia Corporation (LT4.SG)

11,64 -0,58 (-4,75%) Börsenschluss: 09:08PM CEST

Liquidia Corporation

419 Davis Drive
Suite 100
Morrisville, NC 27560
United States
919 328 4400
https://www.liquidia.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 145

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Roger A. Jeffs Ph.D.	CEO & Director	499,57k	N/A	1962
Mr. Michael Kaseta	COO & CFO	589,33k	N/A	1977
Mr. Russell Schundler	General Counsel & Corporate Secretary	508,67k	N/A	1975
Mr. William R. Kenan Jr.	Co-Founder	N/A	N/A	N/A
Dr. Ginger Denison	Co-Founder	N/A	N/A	N/A
Jennifer Almond	Director of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Sarah Krepp SPHR	Vice President of People & Culture	N/A	N/A	N/A
Mr. Jason Adair	Chief Business Officer	N/A	N/A	1974
Dr. Tushar Shah M.D.	Senior Vice President of Product Development	743,75k	N/A	1961
Mr. Scott Moomaw	Chief Commercial Officer	N/A	N/A	1971

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Corporate Governance

Liquidia Corporations ISS Governance QualityScore, Stand 1. April 2024, lautet 10. Die grundlegenden Scores sind Audit: 9, Vorstand: 10, Shareholderrechte: 6, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.